SLCTR/2021/026尚未招募3 期
A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess theefficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant ProteinVaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of ageand older
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Aged 18 years or older on the day of inclusion (Both male and female)
- •2.For persons living with HIV, stable HIV infection determined by participant currently on antiretrovirals with CD4 count > 200/mm3
- •3.Subjects who have had SARS-CoV-2 rapid sero-diagnostic test performed at the time of enrollment to detect presence of SARS-CoV-2 antibodies. Both sero positive and negative subjects will be enrolled however with restriction in sero-positive numbers as a target number of sero-negative subjects need to be enrolled.
- •4.Does not intend to receive an authorized/approved COVID-19 vaccine despite encouragement by the Investigator to receive the authorized vaccine available to them at the time of enrollment.
- •5.A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
- •oIs of non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile.
- •oIs of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 12 weeks after the second study intervention administration.
- •A participant of childbearing potential must have a negative highly sensitive pregnancy test (urine
- •or serum as required by local regulation) within 25 hours before any dose of study intervention.
- •6.Informed consent form has been signed and dated.
- •7.Able to attend all visits and to comply with all study procedures
- •8.Covered by health insurance, only if required by local, regional, or national regulations
排除标准
- •1.Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances
- •2.Dementia or any other cognitive condition at a stage that could interfere with following the study procedures based on Investigator’s judgment.
- •3.Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination based on Investigator’s judgment.
- •4.Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating IM vaccination based on Investigator’s judgment.
- •5.Unstable acute or chronic illness that in the opinion of the Investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures.
- •6.Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ? 38.0°C [? 100.4°F]). A prospective participant should not be included in the study until the condition has resolved or the
- •febrile event has subsided.
- •7.Receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention.
- •8.Prior administration of a coronavirus vaccine (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], SARS-CoV, Middle East Respiratory Syndrome [MERSCoV])
- •9.Receipt of solid-organ or bone marrow transplants in the past 180 days
- •10.Receipt of anti-cancer chemotherapy in the last 90 days
- •11.Participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.
- •12.Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- •13.Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study
研究者
相似试验
招募中
3 期
Safety and efficacy of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and OlderCTRI/2021/06/034442Sanofi Healthcare India Private Limited
进行中（未招募）
3 期
Study of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and OlderCOVID-19JPRN-jRCT2031210159Tanaka Tomoyuki21,046
招募中
1 期
Study on immunogenicity and safety of a meningococcal ACYW conjugate vaccine in healthy infants and toddlersHealthy volunteers (Meningococcal infection)MedDRA version: 20.0Level: PTClassification code: 10027274Term: Meningococcal infection Class: 100000004862CTIS2023-508177-85-00Sanofi Pasteur840
进行中（未招募）
不适用
A PHASE III RANDOMISED, STRATIFIED, PARALLEL-GROUP, MULTI-CENTRE, COMPARATIVE STUDY OF ZD1839 (IRESSA®) 250 MG AND 500 MG VERSUS METHOTREXATE FOR PREVIOUSLY TREATED PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK - IMEXsquamous cell carcinoma of the head and neckEUCTR2004-002662-38-LVAstraZeneca AB477
进行中（未招募）
不适用
A PHASE III RANDOMISED, STRATIFIED, PARALLEL-GROUP, MULTI-CENTRE, COMPARATIVE STUDY OF ZD1839 (IRESSA®) 250 MG AND 500 MG VERSUS METHOTREXATE FOR PREVIOUSLY TREATED PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK - IMEXEUCTR2004-002662-38-LTAstraZeneca AB477